Research Article |
Corresponding author: Abdelrahim Alqudah ( abdelrahim@hu.edu.jo ) Academic editor: Rumiana Simeonova
© 2024 Rawan Abudalo, Abdelrahim Alqudah, Esam Qnais, Rabaa Y. Athamneh, Muna Oqal, Roaa Alnajjar.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Abudalo R, Alqudah A, Qnais E, Athamneh RY, Oqal M, Alnajjar R (2024) Interplay of adiponectin and resistin in type 2 diabetes: Implications for insulin resistance and atherosclerosis. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e114863
|
Aim: The study aims to investigate the association between type 2 diabetes and adipokines, particularly resistin and adiponectin, in insulin resistance. It also explores the potential of the resistin to adiponectin ratio as an indicator for these conditions
Methods: This research involved 198 participants, including 100 patients with type 2 diabetes and 98 controls. It focused on measuring various biochemical parameters like HbA1c, fasting plasma glucose, lipid profiles (low-density lipoprotein, oxidized low-density lipoprotein, triglyceride, total cholesterol), and adipokines (resistin and adiponectin). The study utilized the Homeostasis Model Assessment of Insulin Resistance and Triglyceride-Glucose index to evaluate insulin resistance.
Results: Type 2 diabetic patients exhibited higher levels of HbA1c, fasting plasma glucose, lipid profiles, and resistin, but lower adiponectin levels compared to controls. Adiponectin showed a negative correlation with insulin resistance, while resistin demonstrated a positive correlation. Both adipokines significantly related to atherogenic markers, with adiponectin offering protection against atherosclerosis and resistin augmenting it.
Conclusion: The findings underscore the complex roles of resistin and adiponectin in the pathophysiology of type 2 diabetes, insulin resistance. The resistin to adiponectin ratio could be a useful biomarker for insulin resistance. These insights suggest potential therapeutic strategies for treating diabetes and preventing its complications.
type 2 diabetes, adiponectin, resistin, insulin resistance, HOMA-IR, TyG index, lipid profile
Type 2 diabetes (T2D) is a global epidemic characterized primarily by hyperglycemia resulting from impaired insulin action and secretion (American Diabetes American Diabetes Association 2018). One of the pivotal mechanisms underlying the development of T2D is insulin resistance, wherein cells fail to respond efficiently to insulin, culminating in elevated blood glucose levels (
This impaired glucose metabolism and insulin resistance not only derange metabolic homeostasis but also has profound implications for cardiovascular health. The chronically elevated glucose levels in T2D patients can trigger endothelial dysfunction, a sentinel event in the initiation of atherosclerotic vascular disease(
Atherosclerosis is a primary factor leading to macrovascular disease in diabetic patients due to the constriction of blood vessel walls, especially the arterioles (
In recent years, there has been a rise in interest in the effect of oxidative stress and inflammation in common metabolic disorders such as type 2 diabetes (T2D) (
Emerging in the milieu of metabolic and cardiovascular research are adipokines, bioactive molecules secreted by adipose tissue. These molecules have a crucial role in the control of various physiological processes, such as hunger and satiety, fat distribution, inflammation, blood pressure, and endothelial function they exhibit their functions in several organs, such as adipose tissue, the brain, the liver, blood vessels, and muscles (
These molecules serve as significant regulators of glucose and lipid metabolism and are directly implicated in the pathophysiology of insulin resistance, T2D, atherosclerosis, and CVD (
Conversely, resistin, another adipokine, has been associated with insulin resistance and pro-inflammatory pathways, promoting endothelial dysfunction and atherosclerosis (
Understanding the complex interplay between adipokines, insulin resistance, T2D, and atherosclerosis could unravel new diagnostic and therapeutic avenues for managing metabolic and cardiovascular diseases.
Thus, this study aims to dissect the correlation between adiponectin, resistin, and the adiponectin-to-resistin ratio concerning parameters of glucose metabolism, and lipid profiles in patients with T2D. By exploring these connections, we aspire to provide insights that could be instrumental in devising novel strategies for risk prediction and management in T2D and associated CVD.
This study was a case-control study as indicated by different previous reports (
without any health concerns. The participants were eligible if they were diagnosed with T2D at least six months before the study, lived in Jordan, were older than 18, and were on a sulphonylurea derivative as an oral hypoglycemic drug, and diet treatment. Their casual physical activity ranged from simple household chores to brief post-meal walks, aiding in their energy burn and weight control. Those with Type 1 diabetes or Individuals with cancer, kidney failure, severe liver damage, inflammatory conditions, or those taking insulin, biguanide, thiazolidinedione, or cholesterol-lowering medications were not included in the research.
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the Hashemite University (IRB number: 11/7/2020/2021).
The diagnosis of T2D followed the criteria set by the American Diabetes Association (Anon n.d.), which hinges on a fasting blood glucose (FBG) level of 126 mg/dl or higher after refraining from eating for at least 8 hours. The control group was verified to be free of diabetes by checking the FBG levels on two distinct occasions. Body mass index (BMI) was determined by dividing their self-stated weight (in kg) by the square of their self-stated height (in meters). After resting for 10 minutes, trained nurses measured blood pressure three times from the right arm. Blood was drawn from a peripheral vein into tubes containing heparin. After gentle mixing, these samples were centrifuged at 3,000 rpm at a temperature of 4 °C for a quarter of an hour. Subsequently, the plasma was extracted and preserved at a temperature of -80 °C for later assessments.
HbA1c levels were determined using a kit from Wondfo (China, catalog number: W207). Blood glucose concentrations were evaluated with a colorimetric detection kit by Biolabo (France, catalog number: 80009), all in line with the guidance provided by the respective manufacturers. Insulin was also measured using a commercially available kit (MBS761338, Mybiosource, USA) according to the manufacturer’s instructions.
To assess insulin resistance, Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and triglyceride–glucose (TyG) index were calculated. HOMA-IR was calculated using Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated using a standard formula based on fasting glucose and insulin levels.
HOMA-IR = (Fasting glucose (mg/dL) × Fasting insulin (μIU/mL)/405 (
TyG index was calculated using a standard formula based on fasting triglyceride and glucose levels.
TyG index = ln [fasting TG (mg/dL) × fasting glucose (mg/dL)/2] (
Total cholesterol, low-density lipoproteins (LDL), and, high-density lipoproteins (HDL) were assessed using specific kits from Biolabo (France, catalog numbers: 80106, 90816, and 86516, respectively), following the guidelines provided by the manufacturer. Triglyceride (TG) levels were determined using a kit from Linear Chemicals (Spain, catalog number: 1155005), also in compliance with the manufacturer’s directions. Oxidized LDL (ox-LDL) was measured using a commercially available kit (MBS168574, MyBioSource, USA) according to the manufacturer’s instructions.
Serum concentrations of resistin and adiponectin were determined using commercially available ELISA kits (Mybiosource, USA, MBS355429, and MBS2024009, respectively) as per the manufacturer’s guidelines. The absorbance readings were taken at 450 nm using the ELx800 Microplate Reader by BioTek Instruments, located in Winooski, VT, USA. For every patient, the Resistin/Adiponectin (R/A) ratio was computed by dividing the resistin serum concentration (given in ng/ml) by the adiponectin serum concentration (expressed in ng/ml).
The demographic and clinical characteristics were summarized using means and standard deviations for continuous variables and frequencies for categorical variables. T-tests were used to compare the means between the T2D patients and the controls. P values were calculated, with values below 0.05 considered statistically significant. Pearson’s correlation coefficient was used to assess the relationships between the adipokines (adiponectin, resistin, and the R/A ratio) and other metabolic and cardiac parameters. Again, p-values < 0.05 were considered to indicate a significant correlation.
As depicted in Table
Parameter | Controls (n=98) | T2D (n=100) | P value |
---|---|---|---|
Gender (F/M, n) | 52/46 | 51/49 | |
Age (years) | 62.5 ± 9.4 | 64.0 ± 10.9 | 0.27 |
BMI (kg/m2) | 30.0 ± 2.0 | 29.0 ± 2.4 | 0.13 |
SBP (mm Hg) | 124.2 ± 4.3 | 125.1 ± 2.9 | 0.26 |
DBP (mm Hg) | 85.1 ± 5.2 | 85.5 ± 4.0 | 0.56 |
HbA1c (%) | 4.9 ± 0.5 | 8.2 ± 1.7 | 0.0001 |
FPG (mg/dl) | 83.5 ± 9.2 | 189 ± 44.7 | 0.0001 |
LDL (ng/ml) | 42.4 ± 9.9 | 122.7 ± 9.1 | 0.0001 |
ox-LDL (pg/ml) | 2466.4 ± 483.7 | 2931.7 ± 830.1 | 0.0001 |
TG (mmol/L) | 1.8 ± 0.3 | 2.84 ± 0.2 | 0.001 |
T. Cholesterol (mmol/L) | 4.6 ± 0.3 | 6.1 ± 0.4 | 0.007 |
HDL (ng/ml) | 4421.3 ± 789.2 | 3286 ± 749.3 | 0.0001 |
Insulin (μU/ml) | 4.1 ± 1.6 | 5.1 ± 1.3 | 0.0001 |
HOMA-IR | 0.85 ± 0.3 | 2.4 ± 0.9 | 0.0001 |
TyG index | 4.3 | 4.9 | 0.009 |
Adiponectin (ng/ml) | 4.3 ± 1.6 | 0.6 ± 0.03 | 0.0001 |
Resistin (ng/ml) | 7.5 ± 1.4 | 12.5 ± 1.2 | 0.0001 |
R/A ratio | 1.8 ± 0.8 | 45.0 ± 15.1 | 0.0001 |
The gender distribution was comparable between the two groups, with females and males comprising 53% and 47% of the control group, respectively, and 51% and 49% of the T2D group (p=0.09). Similarly, age did not differ significantly between the groups (62.5 ± 9.4 years for controls and 64.0 ± 10.9 years for T2D patients; p=0.27) as individuals between groups were gender and age-matched to remove the impact of those variables.
Key metabolic parameters highlighted some stark differences between the groups. The HbA1c was markedly elevated in the T2D group (8.2 ± 1.7%) compared to controls (4.9 ± 0.5%) with a significant p-value of 0.0001. Fasting plasma glucose (FPG) in T2D patients was more than double that of controls (189 ± 44.7 mg/dl vs. 83.5 ± 9.2 mg/dl; p=0.0001).
Lipid profile was notably different between the groups. LDL levels in T2D patients were almost three times higher than in controls (122.7 ± 9.1 ng/ml vs. 42.4 ± 9.9 ng/ml; p=0.0001). On the contrary, HDL was found to be significantly lower in T2D patients when compared to controls (3286 ± 749.3 ng/ml vs. 4421.3 ± 789.2 ng/ml; p=0.0001), suggesting that dysregulation of lipoprotein metabolism and dyslipidemia associated with diabetes.
The oxidized LDL (ox-LDL), was significantly elevated in the T2D group (2931.7 ± 830.1 pg/ml) in comparison to the control group (2466.4 ± 483.7 pg/ml; p=0.0001). Similarly, the total cholesterol, triglycerides, insulin levels, HOMA-IR, and TyG (markers of insulin resistance) were also significantly higher in the T2D group.
Adiponectin, which is often decreased in diabetic conditions, was markedly lower in T2D patients (0.6 ± 0.03 ng/ml) compared to controls (4.3 ± 1.6 ng/ml; p=0.0001) while resistin, another adipokine, was elevated in the T2D group (12.5 ± 1.2 ng/ml) compared to controls (7.5 ± 1.4 ng/ml; p=0.0001). The resistin to adiponectin ratio (R/A ratio), an emerging marker of metabolic syndrome and insulin resistance, showed an exceedingly elevated value in T2D patients (45.0 ± 15.1) as opposed to controls (1.8 ± 0.8; p=0.0001).
A correlation analysis was performed to understand the relationship between HOMA-IR, a well-established marker of insulin resistance, and adipokine-related parameters (Table
Pearson’s correlation for serum adiponectin, resistin, and R/A ratio with HOMA-IR in T2D.
Parameter | HOMA-IR | TyG index | ||
---|---|---|---|---|
R | P value | R | P value | |
R/A | 0.69 | 0.0001 | 0.53 | 0.006 |
Resistin | 0.34 | 0.001 | 0.42 | 0.003 |
Adiponectin | -0.89 | 0.0001 | -0.77 | 0.004 |
A robust positive correlation was observed between the R/A (Resistin/Adiponectin) ratio and HOMA-IR, with a correlation coefficient r=0.69 (p=0.0001). Similarly, a positive correlation was documented between R/A (Resistin/Adiponectin) ratio and the TyG index, with a correlation coefficient r=0.53 (p=0.006). This indicates that as the R/A ratio increases, there is a corresponding rise in HOMA-IR TyG index values.
Resistin showed a moderate positive correlation with HOMA-IR. The correlation coefficient was found to be 0.34, and the association was statistically significant with a p-value of 0.001. Similarly, resistin showed a positive correlation with the TyG index with a coefficient of 0.42 and this association was statistically significant with a p-value of 0.003. This result implies that higher levels of resistin are associated with increased insulin resistance. In contrast, adiponectin demonstrated a strong negative correlation with HOMA-IR and TyG index, with a correlation coefficient r=−0.89 and -0.77 (p=0.0001, 0.004, respectively).This inverse relationship suggests that as adiponectin levels decrease, there is a marked increase in HOMA-IR and TyG index values, indicating an enhancement in insulin resistance.
To unravel the relationship between the adipokines (Adiponectin and Resistin), as well as their ratio (R/A) and various metabolic parameters, a detailed correlation analysis was carried out (Table
Pearson’s correlation for serum adiponectin, resistin, and R/A ratio with various parameters in T2D.
Parameter | Adiponectin | Resistin | R/A | |||
---|---|---|---|---|---|---|
r | P value | r | P value | r | P value | |
HbA1c | -0.87 | 0.0001 | 0.78 | 0.0001 | 0.69 | 0.0001 |
LDL | -0.87 | 0.0001 | 0.88 | 0.0001 | 0.77 | 0.0001 |
ox-LDL | -0.97 | 0.0001 | 0.74 | 0.0001 | 0.66 | 0.0001 |
TG | -0.94 | 0.0001 | 0.58 | 0.001 | 0.65 | 0.001 |
T. Cholesterol | -0.30 | 0.01 | 0.49 | 0.001 | 0.49 | 0.001 |
HDL | 0.88 | 0.0001 | -0.74 | 0.0001 | -0.71 | 0.0001 |
Adiponectin demonstrated a strong negative correlation with HbA1c (r=−0.87, p=0.0001). As adiponectin levels decrease, HbA1c values tend to increase, suggesting potential glycemic control disruptions. On the other hand, Resistin positively correlated with HbA1c (r=0.78, p=0.0001), implying higher resistin levels might be associated with poor glycemic control. Moreover, a positive correlation between R/A ratio and HbA1c (r=0.69, p=0.0001) was observed.
Regarding the correlation with lipid profile measures, Adiponectin and Resistin showed strong negative and positive correlations respectively (r=−0.87 and r=0.88, both p=0.0001) with atherogenic LDL. The R/A ratio also displayed a positive correlation with LDL (r=0.77, p=0.0001). However, cardioprotective HDL demonstrated a strong positive correlation with Adiponectin (r=0.88, p=0.0001) and negative correlations with Resistin and the R/A ratio (r=−0.74 and r=−0.71 respectively, both p=0.0001). Furthermore, Adiponectin and Resistin correlated negatively and positively with TG respectively (r=−0.94 and r=0.58, both p=0.001). The R/A ratio also exhibited a positive correlation with TG (r=0.65, p=0.001) while a mild negative correlation was observed between cholesterol and adiponectin (r=−0.30, p=0.01) and moderate positive correlations with Resistin and the R/A ratio (r=0.49 for both, p=0.001). The results provide evidence to support the hypothesis that adiponectin may exert its beneficial effects on cardiovascular disease (CVD) by lowering lipoproteins, such as LDL, TG, and total cholesterol in contrast to resistin.
In a similar pattern, Adiponectin demonstrated a substantial negative correlation with ox-LDL (r=−0.97, p=0.0001), while Resistin showed a positive one (r=0.74, p=0.0001). The R/A ratio displayed a positive correlation with ox-LDL as well (r=0.66, p=0.0001). Thereby, resistin significantly increases lipid peroxidation in contrast to adiponectin.
Type 2 diabetes (T2D) is a multifaceted metabolic disorder. The present study aimed to investigate the clinical characteristics of patients with T2D and controls and then delve deeper into the relationship between insulin resistance (quantified by HOMA-IR and TyG index) and specific adipokines, particularly adiponectin and resistin.
Consistent with established literature, our cohort of T2D patients showed significant differences in several metabolic and cardiovascular parameters compared to controls (American Diabetes Association 2018). Remarkably, HbA1c, FPG, LDL, ox-LDL, TG, and T. Cholesterol were substantially elevated in the T2D group which is consistent with a previous study that found that more than 90% of type 2 diabetic patients in Jordan had dyslipidemia of some kind. Specifically, hypercholesterolemia (77.2%), low HDL (83.9%), high LDL-c (91.5%), and hypertriglyceridemia (83.1%) were all present in this population (
The aberration in these parameters aligns with the recognized pathophysiological alterations associated with T2D (
Resistin and adiponectin have emerged as vital links in the interplay between metabolism and inflammation. The adipokine adiponectin, generally deemed to have insulin-sensitizing properties, showed a strong negative correlation with HOMA-IR, supporting its protective role against insulin resistance (
Another focal point was the understanding of how these adipokines relate to atherosclerosis, a prime mediator of cardiovascular complications in T2D (
The role of oxidized low-density lipoprotein (LDL) as a marker of oxidative stress in the progression of atherosclerosis has been proposed to be substantial, and there exists a correlation between atherosclerotic problems with both diabetes and obesity. Limited research has been conducted on the association between oxidized low-density lipoprotein (Ox-LDL) and adipokines, with a notable absence of studies specifically examining their correlation with resistin and adiponectin. In this study, we formulated a hypothesis regarding a potential correlation between adipokines and Oxidized LDL in an in vivo setting. The findings of our study indicate a positive correlation between concentrations of Ox-LDL and resistin (
Elevated levels of resistin and decreased levels of adiponectin are both associated with detrimental outcomes in cardiovascular health. Resistin, an adipokine, is not just an indicator of adiposity but has been correlated with increased inflammation, endothelial dysfunction, and atherosclerotic progression, which are critical factors in the onset and progression of cardiovascular disease (
The R/A ratio, representing the resistin to adiponectin balance, has been proposed as a better marker for insulin resistance and atherosclerosis than each adipokine alone (
Our findings amplify the intricate roles of resistin and adiponectin in modulating insulin resistance, atherosclerosis, and cardiovascular function in T2D patients. The R/A ratio stands out as a potential diagnostic and prognostic tool. Future studies should focus on mechanistic pathways of adipokines as diagnostic and therapeutic targets.
Conceptualization, A.A. and R.A.D.; methodology, E.Q. and R.Y.A.; software, M.O.; validation, A.A. and E.Q.; formal analysis, R.A.N.; investigation, A.A.; resources, E.Q.; data curation, M.O.; writing—original draft preparation, A.A.; writing—review and editing, R.A.D.; visualization, E.Q.; supervision, R.A.D.; project administration, R.A.D.; funding acquisition, R.A.D. All authors have read and agreed to the published version of the manuscript.
All participants provided a consent form prior to joining the study.
The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
The authors would like to thank all participants in this study.